REFERENCES
1. Mannucci PM, Tuddenham EGD. The Hemophilias — From Royal Genes to
Gene Therapy. N Engl J Med , 2001 344: 1773–1779.
2. Baglin T. The measurement and application of thrombin generation. Br
J Haematol , 2005 130: 653–661.
3. Inhibitors in congenital coagulation disorders - Key - 2004 - British
Journal of Haematology
4. Owaidah T, Momen AA, Alzahrani H, Almusa A, Alkasim F, Tarawah A,
Nouno RA, Batniji FA, Alothman F, Alomari A, Abu-Herbish S, Abu-Riash M,
Siddiqui K, Ahmed M, Mohamed S, Saleh M. The prevalence of factor VIII
and IX inhibitors among Saudi patients with hemophilia. Medicine
(Baltimore) , 2017 96
5. Aledort L, Ljung R, Mann K, Pipe S. Factor VIII therapy for
hemophilia A: current and future issues. Expert Rev Hematol , 2014 7:
373–385
6. Scott LJ, Kim ES. Emicizumab-kxwh: First Global Approval. Drugs ,
2018 78: 269–274.
7. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G,
Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N,
Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in
Hemophilia A with Inhibitors. N Engl J Med , 2017 377: 809–818.
8. Nogami K. Bispecific antibody mimicking factor VIII. Thromb Res ,
2016 141: S34–S35.
9. Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso
ME, Schmitt C, Jiménez-Yuste V, Kempton C, Dhalluin C, Callaghan MU,
Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A with
Inhibitors. N Engl J Med , 2018 379: 811–822
10. Le Quellec S. Clinical Evidence and Safety Profile of Emicizumab for
the Management of Children with Hemophilia A. Drug Des Devel Ther , 2020
14: 469–481.
11. Young G, Sidonio RF, Liesner R, Oldenburg J, Chang T, Uguen M,
Dhalluin C, Schmitt C, Levy GG, Shima M, Mahlangu J. HAVEN 2 Updated
Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy,
Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab
Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors.
Blood , 2017 130: 85–85.
12. Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic
and laboratory management of patients with haemophilia and inhibitors.
Haemophilia , 2008 14: 20–27
13. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin
generation test for dose monitoring of bypassing therapy in hemophilia
patients with inhibitors undergoing elective surgery. Blood , 2010 116:
5734–5737.
14. Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier
C. Use of thrombin generation assay to personalize treatment of
breakthrough bleeds in a patient with hemophilia and inhibitors
receiving prophylaxis with emicizumab. Haematologica , 2018 103:
e181–e183
15. Mathieu S, Crampe C, Dargaud Y, Lavigne-Lissalde G,
Escuriola-Ettingshausen C, Tardy B, Meley R, Thouvenin S, Stephan JL,
Berger C. Challenges of the management of severe hemophilia A with
inhibitors: two case reports emphasizing the potential interest of a
high-purity human Factor VIII/von Willebrand factor concentrate and
individually tailored prophylaxis guided by thrombin-generation test.
Blood Coagul Fibrinolysis , 2015 26: 940–945.
16. Coppola A. Treatment of hemophilia: a review of current advances and
ongoing issues. J Blood Med , 2010 183.
17. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent
therapy. J Thromb Haemost JTH , 2012 10: 1478–1485.
18. New drug: Emicizumab for haemophilia A. Aust Prescr , 2019 42: 29
19. Shima M, Nogami K, Nagami S, Yoshida S, Yoneyama K, Ishiguro A,
Suzuki T, Taki M. A multicentre, open-label study of emicizumab given
every 2 or 4 weeks in children with severe haemophilia A without
inhibitors. Haemoph Off J World Fed Hemoph , 2019 25: 979–987.
20. Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G,
Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C,
Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. The effect of
emicizumab prophylaxis on health-related outcomes in persons with
haemophilia A with inhibitors: HAVEN 1 Study. Haemoph Off J World Fed
Hemoph , 2018.
21. Kruse-Jarres R, Callaghan MU, Croteau SE, Jimenez-Yuste V, Khoo L,
Liesner R, Matsushita T, Recht M, Young G, Chang T, Dhalluin C, Mu Y, Xu
J, Devenport J, Ko RH, Solari P, Oldenburg J. Surgical Experience in Two
Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with
Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood , 2017 130:
89–89.
22. Dargaud Y, Lienhart A, Meunier S, Hequet O, Chavanne H, Chamouard V,
Marin S, Negrier C. Major surgery in a severe haemophilia A patient with
high titre inhibitor: use of the thrombin generation test in the
therapeutic decision. Haemophilia , 2005 11: 552–558
23. Srivastava, Chandy, Sunderaj, Lee, Daniel, Dennison, Nair, Mathews,
Anderson, Nair, Moses, Sudarsanam. Low-dose intermittent factor
replacement for post-operative haemostasis in haemophilia. Haemophilia ,
1998 4: 799–801
24. Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G.
Management of perioperative hemostasis in a severe hemophilia A patient
with inhibitors on emicizumab using global hemostasis assays. Ther Adv
Hematol , 2019 10.
25. Santagostino E, Oldenburg J, Chang T, Xu J, Chebon S, Doral M.
Surgical Experience from Four phase III Studies (Haven 1-4) of
Emicizumab in Persons with Haemophilia A (PwHA) with or without FVIII
inhibitors, 2019.